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a b s t r a c t
Risk assessment describes the impact of a particular hazard as a function of dose and exposure. It forms
the foundation of risk management and contributes to the overall decision-making process, but is not its
endpoint. This paper outlines a risk analysis framework to underpin decision-making in the area of aller-
gen cross-contact. Specifically, it identifies challenges relevant to each component of the risk analysis:
risk assessment (data gaps and output interpretation); risk management (clear and realistic objectives);
and risk communication (clear articulation of risk and benefit). Translation of the outputs from risk
assessment models into risk management measures must be informed by a clear understanding of the
model outputs and their limitations. This will lead to feasible and achievable risk management objectives,
grounded in a level of risk accepted by the different stakeholders, thereby avoiding potential unintended
detrimental consequences. Clear, consistent and trustworthy communications actively involving all
stakeholders underpin these objectives. The conclusions, integrating the perspectives of different stake-
holders, offer a vision where clear, science-based benchmarks form the basis of allergen management and
labelling, cutting through the current confusion and uncertainty. Finally, the paper recognises that the
proposed framework must be adaptable to new and emerging evidence.
 2014 ILSI Europe. Published by Elsevier Ltd. All rights reserved.
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1. Introduction
In the previous papers, we demonstrated that the risk from
unintended food allergens can be assessed and quantified using
the same approaches as for other contaminants. However, risk
assessment sets out the (health) consequences of exposure, but
does not indicate whether the risk in question is acceptable or
not, or at what point it would become so. It also does not deal with
the challenges of implementation. This paper discusses the ele-
ments that need to be considered in arriving at such a conclusion.
It starts by examining the meaning of the risk assessment endpoint
generated by the methodologies previously described in the risk
assessment paper and how these might be communicated to the
different stakeholders. It then considers the implications, benefits
and potential pitfalls for each group of adopting specific reference
values, in particular those proposed for the Allergen Bureau of Aus-
tralia and New Zealand’s Voluntary Incidental Trace Allergen
Labelling (VITAL) system. Finally, it offers a vision for allergen
management as it moves forward. The framework discussed is
intended to be applied to manage the risk from allergen cross-
contact in foods for normal consumption. It is not intended to
provide the basis for claiming that a product is ‘‘free-from’’ a specific
allergen, although it may help in deriving criteria for doing so.
2. Risk assessment endpoint: understanding the model outputs
Risk assessment is the process whereby the impact of a hazard
is estimated, and is a critical prerequisite to management of the
risk. However, deciding on appropriate risk management measures
requires that stakeholders agree on what degree of risk they ac-
cept. Both the frequency of adverse effects and the nature of those
effects in terms of severity, duration and reversibility will deter-
mine acceptability (or perhaps more correctly tolerability). Severe
and irreversible effects will thus be tolerated to a lower extent than
those with a lesser impact on health, as will those whose conse-
quences are seen as unpredictable (Madsen et al., 2012). The mod-
els described in the previous paper (ref) predict the potential
proportion of allergic people reacting to a range of doses of the spe-
cific allergen (dose distributions) or the total number of reactions
expected if a given distribution of allergen is present in a food
product of interest. However, this information may not clearly ad-
dress the potential of these allergens to cause serious or irrevers-
ible effects on health, which drives much of the public health (as
well as individual) concern on the need for current allergen label-
ling and strict avoidance policies (Madsen et al., 2010, 2012). Thus,
the likely severity of a reaction at any given dose is also critical to
the risk assessment and consequent risk management measures.
The scarcity of data on the relationship between dose and severity
therefore remains an important gap in characterising the risk from
exposure to food allergens. Furthermore, a common understanding
among stakeholders about the endpoint(s) which the risk assessment
seeks to evaluate and quantify is needed to achieve transparency
and eventual acceptance of the risk management strategy.
To date only limited information has emerged regarding the
relationship between food challenge data and clinical reactions in
daily life. During low dose challenge, patients are closely moni-
tored and once a reaction has clearly taken place (usually if objec-
tive symptoms occur) the challenge is stopped and the patient
treated (if necessary). Consequently the reaction during challenge
will usually be not as severe as reactions can be in daily life. There
is also no clear relationship between minimum eliciting dose and
severity (Rolinck-Werninghaus et al., 2012). However one can as-
sume that if threshold data are derived from a representative pop-
ulation these factors will minimally influence the threshold
distribution itself. To further illustrate the health implications of
findings from threshold distributions, challenge studies have been
proposed to evaluate whether the dose corresponding to the ED05
indeed leads to responsiveness in 5% of the patients and to provide
information on the severity profile of the reactions observed
(Zurzolo et al., 2013) Theoretically reactions during DBPCFC can
be influenced by preceding doses in the dose escalation, a problem
which is avoided by challenge with a single dose. In real life,
thresholds and subsequent reactions may also be influenced by a
number of known and unknown factors, such as exercise, infection,
stress and more. Quantification of the potential effects, if any, of
these factors will require further research.
Allergic reactions can range in severity from barely perceptible
subjective symptoms, such as itching or tingling in the mouth, to
mild to moderate objective symptoms, such as hives, lip swelling,
nasal congestion, diarrhea or vomiting, to severe breathing difficul-
ties and life-threatening anaphylactic shock. Clearly the implica-
tions of these different types of reactions from both an individual
as well as a public health perspective differ greatly and need to
be taken into account in risk assessments. In the USA, the Food
Allergen Labeling and Consumer Protection Act (FALCPA) refers
to the labelling exemption concept of an ‘‘allergic response that
poses a risk to human health’’ as what management of the risk
seeks to avoid. This terminology implies that there are some aller-
gic responses which can be deemed not to pose a risk to human
health. This also accords with the observation that the concept of
risk itself according to many definitions, as well as in the public
mind, is associated not only with the probability of an adverse ef-
fect, but also with consideration of its likely severity.
One of the difficulties in applying this concept in food allergen
risk assessment has been the perception that severity is unpredict-
able, such that a history of non-severe reactions is no guarantee
that future reactions will not be more severe. Extrinsic factors, such
as exercise and medication can undoubtedly modulate severity, as
discussed already. However, when evaluating conclusions that
severity is unpredictable, due regard must be paid to the fact that
those conclusions are often based on circumstances where no infor-
mation exists on a very important modulator of effect, namely dose.
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Current models for assessing the risk from the unintended pres-
ence of allergenic constituents through cross-contact focus solely
on a calculation of the probability of any reaction (or any objective
reaction) without any regard to its health impact. This reflects the
available data. However, even a fairly cursory examination of the
outputs of these models reveals that the number of predicted reac-
tions far exceeds the numbers that are recorded. Thus a fairly
approximate calculation based on the paper of Rimbaud and col-
leagues (Rimbaud et al., 2010) predicts about 65,000 reactions to
peanut in France from chocolate alone, which is 2–4 times higher
than the number of severe allergic reactions from all combined
food allergens estimated by Rance et al. (2005). This may not indi-
cate solely inevitable inaccuracies and uncertainties in the risk
assessment model, but could reflect, among other factors, that a
large proportion of reactions at low doses have such limited impact
on health that they are, and will always remain invisible to any
monitoring or recording system. To put the issue of contamination
in perspective, in a small study on the relationship between dose of
peanut and the occurrence of anaphylaxis in an experimental set-
ting, Wainstein and colleagues (Wainstein et al., 2010) showed
that the minimum dose associated with an anaphylactic reaction
was the equivalent of 5 mg of peanut protein (20 mg peanut). This
is 25-fold greater than the mean unintended peanut intake per oc-
casion per week estimated by Rimbaud and colleagues (0.2 mg)
and the proposed VITAL reference dose for peanut (Allergen
Bureau, 2012), (Allen et al., 2013; Taylor et al., 2014).
In considering whether uncertainty factors need to be applied
to reference doses derived from dose distributions, it is useful to
remember that the model predictions for any given dose represent
the total number of reactions, of which a relatively high proportion
may be expected to be mild or inconsequential. If the risk assess-
ment goal sought through the application of reference doses (e.g.
in VITAL) is to minimise the number of reactions which would be
considered harmful to human health, then one could argue that
the models themselves incorporate their own inbuilt uncertainty
factor. Notwithstanding this observation, more knowledge on the
relationship between dose and severity would help to improve risk
assessments and agreement on an accepted level of risk. Food chal-
lenge data provide relatively limited, but nevertheless useful infor-
mation in this regard and analysis of the Europrevall dataset has
examined ways to use it in risk assessments.
Another, complementary, approach would be to use the Delphi
technique to generate a consensus among clinical experts about
the likelihood of a severe reaction and the relative severity of the
associated responses for an appropriate range of very low doses,
such as those proposed by the VITAL Scientific Panel and adopted
by this Expert Group. These probability and severity elements could
then be incorporated into probabilistic risk assessment models.
How a risk is expressed can also influence how it is perceived.
However, a critical first step is to ensure that whatever form of
expression is used is accurate. Typically, the result of a risk assess-
ment is expressed as the likelihood of a reaction (e.g. 1%, 1 in a
million, etc.). However, a risk assessment includes intake data
(even if inadequate) and such data are expressed as intake over
a specified period of time. Thus the resulting expression of risk
at the very least should indicate the time denominator, or where
appropriate the number of predicted reactions per unit of product
and, in ideal terms, reactions per estimated meal consumption of
product.
Beyond this, careful use of terminology is necessary to reflect the
quantitative models. For instance, a reference dose (ED01) can be
described equally accurately as the dose equivalent to a 1 in 100
chance of a reaction or the dose which offers 99% protection to the
allergic population. Results can also be expressed in a variety of
ways for an individual, such as the number of years this individual
could be expected to live without experiencing a reaction. One
possible way forward would be to anchor those risk determinations
by reference to other risks of a similar nature (Madsen et al., 2010).
3. Risk management: translating the risk assessment to
protection of public health
Risk management can only take place effectively if its aims are
clearly set out and understood. A clear description of risk manage-
ment objectives should therefore precede any risk assessment as it
will guide the collection of the appropriate data. In particular, the
potential constraints on these objectives need to be identified and
addressed. Critical considerations include:
– Feasibility within operational and regulatory constraints: it is
important to ensure that any proposed levels do not have the
unintended consequence of making the situation worse. A
highly conservative approach, if it resulted in reference doses
that were beyond the technological capabilities of most food
manufacturing facilities, could result in an increase in precau-
tionary labelling, at least in the short to medium term. Indeed,
this feasibility issue was one of the concerns acknowledged by
the US FDA in its assessment of gluten thresholds or action levels
for gluten-free label rulemaking [Federal Register of August 5,
2013 (78 FR 47154)]. The complexity involved in achieving these
objectives therefore needs to be discussed with all stakeholders.
– Need to balance a number of potentially conflicting
considerations:
 Potential effects on other safety parameters (microbiologi-
cal, chemical).
 Potential adverse environmental aspects of e.g. cleaning
protocols.
 Potential wastage of otherwise safe food product.
 Potential over-use of precautionary statements – If a precau-
tionary warning is used, how well do allergic consumers
adhere to it?
 Decreased quality of life for allergic consumers due to con-
strained food choices from over-use of precautionary state-
ments and, conversely, due to increased fear and anxiety of
reactions to products without such statements. Also, con-
strained food choices may lead some individuals to begin
disregarding precautionary labels and lead to ill-advised
risk-taking behaviour.
More generally, defining risk management objectives includes
clarity about the scope of the risk management activity, what it ap-
plies to (and equally importantly, what it does not apply to) as well
as what type of adverse events it seeks to mitigate, among the
range of reactions that a condition like food allergy can produce.
3.1. Scope: risk management objectives in relation to quantitative risk
assessment related to cross-contact
Management of allergen risks encompasses a wide range of
activities, including setting of ingredient specifications, verification
of label artwork, checks on packaging materials, production plan-
ning, etc. Specific management of cross-contact risks is only one
of those elements. Risk as described and discussed in this series
of reports focusses on the risk posed by the unintended presence
of allergens through cross-contact at any point in the supply chain.
It therefore excludes the risk arising from other activities within
allergen risk management, for instance, undeclared allergen as a
result of mislabelling or mispackaging.
Quantitative risk assessment using reference doses aims princi-
pally at minimising the risk from the presence of unintended aller-
gen. However, it could also inform decisions regarding mandatory
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ingredient labelling regulations, including exemptions from aller-
gen labelling requirements for highly processed ingredients from
allergenic foods that have been demonstrated not to pose an aller-
genic risk. Food labelling regulations in most countries mandate
the source labelling of all ingredients derived from or containing
protein from commonly allergenic foods, unless exempted. Ingre-
dients currently exempted from source labelling include those ex-
empted either by the prevailing food law (e.g. highly refined oils in
the US) or by a specific exemption process (several ingredients in
the EU) and represent a very small number of ingredients. Many
ingredients labelled as allergens on the market contain very high
levels of protein from the allergenic source (e.g. casein from milk
or semolina flour from wheat) and represent a clear risk to allergic
individuals. However, others contain either very low (e.g. soy leci-
thin or food-grade lactose from milk) or no detectable protein from
the allergenic source based on the limits of current detection
methods (e.g. milk-based flavourings such as butter ester). More
importantly, these latter ingredients remain labelled and avoided
by consumers even though there is little to no evidence that resid-
ual allergenic protein from such ingredients would pose a clinically
significant risk to public health. Thus, required source labelling of
ingredients, in cases where very little allergenic protein remain
and residual risk is extremely low, may serve to further restrict
the diets of food-allergic consumers with little or no public health
benefits.
Up to now, decisions regarding the necessity of source labelling
for ingredients with very low levels of protein from the allergenic
source have not been based upon quantitative risk assessment.
However, since the allergen concentrations of ingredients as well
as the amount(s) of the same ingredients added to the product
are both known with reasonable precision, allergen content in this
type of product labelling scenario is likely easier to estimate and
control by the food industry compared to scenarios involving unin-
tended allergens. Thus, it is conceivable that an accurate risk
assessment of allergen levels in the final product from these ingre-
dient scenarios can be achieved, and this information can ulti-
mately inform risk-based decisions on the necessity of source
labelling for specific food ingredients as well.
3.2. Sphere of applicability: population risk versus individual risk
The allergen risk assessment approach outlined above ad-
dresses allergenic risk at the population level, aiming to provide
a defined level of protection. This approach does not, and indeed
cannot, indicate what risk would be incurred by any specific indi-
vidual under specific circumstances. In this regard, it cannot guar-
antee that every individual would be protected, but can only
provide a probability estimate. This approach, therefore, is not dis-
similar from chemical risk assessment, in which the accepted risk
is defined in terms of any additional case of adverse health effect
(e.g. cancer) over a lifetime without information about which indi-
vidual(s) will be the additional case(s). While bearing in mind the
limitations above, information from the risk assessment can be
used in conjunction with other information (e.g. clinical knowledge
of their minimum eliciting dose and pattern of reactivity) specific
to the person concerned to provide helpful information about the
risks incurred by that person. As discussed earlier, determining
what is safe (what risk is accepted for individual allergic consum-
ers) using a population approach is a shared responsibility be-
tween the different stakeholders.
3.3. Nature of the adverse effect(s) to be mitigated
Insofar as preventing serious and irreversible adverse effects is
more important than avoiding transient mild ones, the risk man-
agement objectives must take into account the nature of the
adverse effect(s) that are likely to occur at the limits (e.g. reference
doses) used to guide risk management actions. Informed stake-
holders in the field of food allergy now accept that total elimina-
tion of the risk of reaction from incidental exposure to allergen is
not feasible (Madsen et al., 2012). As discussed previously, the
manifestations of food allergy range from barely perceptible symp-
toms to severe anaphylaxis, which can lead to death. Thus the prin-
cipal risk management objective could be to improve food safety
for food allergic consumers by preventing severe or life-threaten-
ing reactions from unintended (not undeclared) presence of aller-
gen, while minimising risk for other types of reactions to
manageable levels. A clear description of the risk management
objectives will also help subsequent risk communication. Once
the principal risk management objective has been agreed, subsidi-
ary objectives can be defined which contribute to the realisation of
this principal objective. One such objective could be for industry to
harmonise the application of precautionary labelling and make it
more transparent to other stakeholders. This would increase the
understanding of its meaning and thereby enhance its credibility
and decrease risk taking among allergic consumers. The reference
doses defined by dose distribution modelling, as well as the out-
puts of probabilistic risk assessment need to be interpreted in
the light of those risk management objectives. With regards to nat-
ure of the adverse effect, in particular, it is important to remember
that those outputs represent numbers of reactions but do not indi-
cate how many of those reactions might be severe.
A particular consideration for the risk management objectives
will be achieving the appropriate balance in terms of the proportion
of products bearing a precautionary label. Precautionary ‘may con-
tain’ labelling is applied to a significant number of food products in
certain categories (Pieretti et al., 2009) and clinical guidelines con-
servatively recommend that all patients with food allergies avoid all
products with this type of labelling (Boyce et al., 2010). Since this
labelling is often applied to products which present minimal risks
arising from the unintended presence of the allergenic food, one
of the consequences of this labelling is that it significantly restricts
the choice of potentially safe foods available to allergic consumers.
This food choice restriction not only negatively impacts the quality
of life of these individuals but increases the risk of a nutritionally
deficient diet for food allergic consumers as well (Christie et al.,
2002). Importantly, as evidenced by a sizable and growing percent-
age of consumers who report distrust and general disregard for pre-
cautionary label statements, with some types of statements (e.g.,
‘‘produced in a facility’’) likely to be disregarded over others (e.g.
‘‘may contain’’) (Barnett et al., 2011a; Hefle et al., 2007; Leung
et al., 2003b, 2003a), the large number of products carrying precau-
tionary labelling detracts from the value of the warning in those
cases where it is appropriate. As a general principle, precautionary
labelling should only be used after a thorough risk assessment
and where actions intended to minimise the likelihood of allergen
cross contamination have not been able to reduce the risk suffi-
ciently. Over the last decade, much progress has been made in filling
a number of the data and knowledge gaps that prevented an ade-
quate assessment of the risk, as detailed earlier in this report.
These developments lead to a realistic possibility that a solid and
consistent, science-based framework for dealing with specific food
incidents (product non-conformance with potential safety implica-
tions) and for managing the risks posed by various scenarios involv-
ing allergen cross contamination can also be achieved. Such a solid
framework also ensures that a consistent risk-based compliance
and enforcement approach can be adopted, and helps to maintain
a proportionate response to different incidents within a country.
Above all, a broadly similar approach might be envisaged which is
consistent between countries across the EU and beyond. By fostering
development of the new knowledge on thresholds and its transla-
tion into an innovative risk assessment concept, businesses can
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develop and apply a comprehensive and self-regulatory approach
which encompasses labelling of allergenic food used deliberately
as ingredients, risk-based allergen cross contamination warnings
and also allergy ‘free from’ claims. Such developments offer the pos-
sibility of risk management objectives, based on sound evidence and
scientific understanding, with a quantitative basis where applicable.
3.4. Feasibility and practicality: factors in minimising risk
Determining what might be a tolerable risk needs to balance the
level of residual risk against the benefits to the allergic consumer of
having a transparent, science-based framework that allows more
confidence and trust in the precautionary labelling being provided.
If the action level/threshold is set as low as possible, this will appear
to provide greater protection. However, setting a very low level
could mean that businesses might not be able to work to such a level
and still produce food products at realistic cost. It could also result in
many more food products having precautionary labelling, thereby
severely curtailing the choice of foods. The framework therefore
needs to be both feasible and practicable. If it does not meet those
conditions, then adoption will be reluctant and take-up by industry
will be poor. Moreover, the framework will fail to meet the objec-
tives it was designed to address or, even worse, might lead to unin-
tended consequences opposite to those desired. One example of this
latter point might be an extension of precautionary labelling, rather
than a reduction or stabilisation. This could lead to an increase in
potential direct or indirect adverse health consequences from not
only fewer food choices for allergic consumers but also potential
for greater risk taking and ill-advised consumption, rather than
avoidance, of products with precautionary label statements.
The reference doses based on VITAL and proposed in this report
are intended to strike a balance at a point where reactions are min-
imised through a combination of a high level of protection and
more credible and potentially less frequent precautionary label-
ling. Although better data are becoming available to support the
reference doses, little evidence currently exists to quantify the ef-
fect of greater credibility and more restricted use of precautionary
labelling. Thus, these proposals should be seen as a starting point
based on current knowledge, which will be built upon and refined
as this knowledge develops.
The extent to which the proposed reference doses can be used
to improve (without extending) precautionary labelling will de-
pend to a great extent on the technology and operational charac-
teristics of different sectors. For instance, operations where full
clean-in-place (CIP) sanitation exists will generally meet the condi-
tions more easily than those where the handling of dry materials
and inaccessible machinery components preclude such techniques.
In its current form, the framework only applies directly in situa-
tions where cross-contact is in non-particulate form and where
the unintended allergen is mixed fairly evenly into the product.
Thus, this framework may affect only a proportion of products
which bear a precautionary label. However, better understanding
of risks from the use of the framework in these product scenarios
should also build confidence in the development of risk assessment
approaches for particulate contamination scenarios as well.
4. Risk Communication: establishing a common understanding
of the risk
Risk analysis consists of several steps of which risk assessment
(science-based) and risk management (policy-based) have been
discussed. Risk communication is the third major component.
The Codex Alimentarius Commission Procedural Manual, Nine-
teenth Edition (2010) defines it as ‘‘The interactive exchange of infor-
mation and opinions throughout the risk analysis process concerning
risk, risk-related factors and risk perceptions, among risk assessors,
risk managers, consumers, industry, the academic community and
other interested parties, including the explanation of risk assessment
findings and the basis of risk management decisions.’’ This definition
makes it explicit that risk communication is not a passive process
of transmitting information, but an interactive and iterative one
encompassing all stakeholders, including allergic consumers,
where it concerns food allergens. Thus improving safety for people
with food allergies requires much better communication with both
allergic patients and health professionals involved in their care.
Trust in the agent delivering information lies at the heart of
acceptance of any residual risk (Cvetkovich and Earle, 1992). A ro-
bust risk assessment is a necessary, but not sufficient condition for
such trust. Confidence that the agent who has undertaken that risk
assessment has acknowledged the interests of all those potentially
affected is essential to that trust. Risk communication can be con-
sidered from a variety of perspectives, including those of the actors
involved (public, private), target areas and the nature of the com-
munication (proactive, reactive). Public risk communication con-
cerns those areas where the public authorities are expected to
take a view on, and respond to the risk, while private risk commu-
nication covers all other aspects. One example of public risk com-
munication would be that undertaken by regulators in highlighting
the standards and practices to which businesses must adhere, as
well as explaining the trade-offs between different actions. Private
risk communication, for example by businesses or trade associa-
tions, can also aim at similar targets, although it may arguably be
less effective because of the agent delivering the message and its
perceived interests. Much private risk communication will tend
to be reactive, for instance in response to an incident where the
safety of consumers may have been compromised. Recall notices
would be a good example and need not have a wholly negative im-
pact on trust, if well-executed. In those circumstances they can
demonstrate high standards of care for customers by the affected
business. Of course, any positive effect would soon evaporate and
turn into reputational damage if such recall notices were to be-
come frequent. Proactive risk communication of industry’s role in
driving the development of explicit defined standards for allergen
management and its collaboration with other stakeholders offer a
strategic chance for industry to engender more trust among con-
sumers as appropriate active risk communication will increase
trust among consumers and foster consumer loyalty.
Of course, the food industry is already communicating food
(allergen) risks to consumers through mandatory declaration of pri-
ority allergens as ingredients and through precautionary labelling.
However, evidence shows that communication of the risk posed
by the unintended presence of allergens is largely failing, as at-
tested by allergic consumers’ understanding of, and trust in the pre-
cautionary labelling which delivers that information (Barnett et al.,
2011a). In part, this lack of trust lies at the door of the best efforts of
some manufacturers to be transparent about the nature of the risk
their products pose. For instance, differentiated statements, such as
‘‘made on a line or in a factory that also handles allergen X’’ rather
than simply ‘‘may contain allergen X’’ can be an attempt to help the
allergic consumer, or at least respond to demands for more mean-
ingful information. However, since many consumers are instructed
to avoid all products with precautionary allergen labelling, the large
number and variety of these statements may not only create confu-
sion among consumers but eventual distrust and even complete
disregard of these statements (Cochrane et al., 2013). Disregard of
precautionary statements by allergic consumers not only under-
mines the intent of precautionary allergen labelling but also con-
tributes to risk-taking behaviours and potential for adverse
reactions since a small but notable percentage of products with
these statements contain hazardous levels of allergen (Crotty and
Taylor, 2010; Hefle et al., 2007). Another factor contributing to this
distrust may be the lack of common and explicit criteria used to
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apply precautionary labelling and the resulting over-use, as well as
its use under circumstances where the message intrinsically lacks
credibility (e.g. on bottled mineral water). This fosters, or rein-
forces, the belief that precautionary labelling aims more to protect
the manufacturer from liability than the consumer from harm
(Slovic, 1993; Slovic and MacGregor, 1994; Siegrist, 2000 2003;
Renn, 1991; Lofstedt and Horlick-Jones, 1999; Leiss, 1996; Kasper-
son et al., 1992; Earle and Cvetkovich, 1995; Barnett et al., 2011b,
2011a; Crotty and Taylor, 2010). Restoring confidence in precau-
tionary labelling and thereby its effectiveness will require not only
explaining the benefits in terms of safety that the risk analysis
framework will bring, but actively engaging all stakeholder groups
in reaching agreement on the level of risk that can be accepted, as
discussed in other sections. A critical aspect will be to explain
how the application of such a framework to precautionary labelling
will help reduce the anxiety experienced by allergic consumers and
those caring for such consumers (Madsen et al., 2012).
5. Stakeholder perspectives
5.1. Allergic consumers
Communication to allergic consumers involves a high level of
engagement by and with patient advocacy groups. Consumers tend
to buy products on the basis of trust, experience and recommenda-
tion (Slovic, 1993; Barnett et al., 2011a). Consumers would expect
that any product that is for sale is safe (subject to any exclusions
for specific groups), and that safety would be assured by the pro-
ducers and retailers as well as by regulatory bodies. This thinking
is indeed embedded in European Food Law. All the communication
to consumers via the label or package is also presumed to be part of
a mandatory legal requirement. Precautionary warnings are seen
by consumers as being part of this mandatory information,
although in truth such warnings are voluntary and not legally reg-
ulated beyond the general requirements of food and consumer pro-
tection laws. Also, given the significant percentage of products that
carry such statements [Pieretti et al., 2009], consumers are con-
cerned that precautionary labelling is used indiscriminately, and
this has undermined its value as a risk communication tool. [Hefle
et al., 2007] The perception of such labels in many cases is that
they do not reflect a real risk of contamination, but rather are an
attempt by producers to avoid liability. Consumers appreciate
industry’s attempts to provide more information (‘‘ingredients
nut free’’, packaged in factory that uses nuts in other products’’
etc.), but they remain sceptical about the accuracy of these state-
ments (Barnett et al., 2011a).
From the perspective of allergic consumers, an important consid-
eration is that the implementation and acceptance of the proposed
framework needs an appropriate communication strategy. Only
then can allergic consumers be expected to understand it. A current
limitation in this understanding is that most consumers do not know
their individual allergen thresholds. Diagnostic testing does not gen-
erally provide this information, and there is a lack of population sur-
veys of allergic consumers that have addressed what consumers
know or understand about thresholds. Thus, consumers must rely
on their personal beliefs or experiences of where their threshold lies
when they encounter food products with precautionary labels. Some
consumers may tend to be more cautious while others take more
risks, and these tendencies likely determine their consumption
behaviours. As noted previously, strict avoidance can lead to re-
duced food choices and nutrition for consumers, which negatively
impact quality of life. On the other hand, complete disregard for pre-
cautionary labels would increase the risk to allergic cconsumers as
this would contribute to consumption of foods with potentially haz-
ardous levels of allergen (Hefle et al., 2007).
In light of consumer uncertainty about thresholds, an important
feature of the new framework and indeed one of its strengths, is
that the transparency of the approach lends itself well to the devel-
opment of a communication strategy. Communicating a message
that reference doses are associated with a certain risk of reaction
provides important information about the safety of the product
but also challenges the notion held by consumers that safe prod-
ucts are not expected to cause adverse effects under (almost) all
circumstances. Thus, communication of the framework will require
careful elaboration of the strategy and messages. There are prece-
dents for such communication, for instance the microbiological
risks of Listeria to certain groups, but the message here is more
complex. It will require communication at different levels and can-
not be achieved without full involvement of all stakeholders. There
is also an important need to engage consumers about their under-
standing of thresholds and reference doses and about their views
on risks, especially in light of potential benefits of having more
products (with less precautionary labelling) available to them.
5.2. Clinicians and other health professionals
Health professionals such as clinicians, dieticians and nurses
encounter daily the problem of how to advise patients adequately
about risks from low level allergen exposures in food products.
However, these advisors may not use a consistent approach in
explaining risks to patients/consumers. A significant part of this
problem is that there are currently no diagnostic methods available
that can help health professionals accurately understand what
allergen threshold doses their patients are reacting to or how se-
vere a patient’s response would be to that reactive dose. For exam-
ple, prior clinical history of reaction severity has little utility in
predicting which individual will have a future severe reaction
(Boyce et al., 2010) and food-specific IgE levels, although higher
levels predict those individuals likely to fail food challenge, do
not consistently correlate with eliciting challenge doses or reaction
severity (Rolinck-Werninghaus et al., 2012). Food challenges,
although helpful in identifying the lowest eliciting allergen doses
for a given individual, are not always performed in patients. When
they are performed, clinicians are not comfortable giving patients
avoidance advice based on these challenge results since data show
that individual thresholds may vary over time (Leung et al., 2003a).
In addition to poor diagnostic tools, health professionals are not al-
ways informed about food industry practices and thus tend to
share patients’ misunderstanding of the regulatory status of pre-
cautionary labelling. Anecdotally, different recommendations
about avoidance of foods bearing precautionary label may be given
to patients/consumers by health professionals based on personal
beliefs about labelling rather than a full understanding of the risks.
Current recommended practice is to advise a given patient to
avoid any exposure to the allergen, by avoiding any food containing
the allergen either as an ingredient or as a possible contaminant
(precautionary label statement) (Boyce et al., 2010). This approach
is understandable when the intrinsic allergenicity of a food is
known not to vary, e.g. peanut in loose confectionary or in wrapped
cereal bars. Anecdotally, however, different avoidance advice may
be given according to different clinical scenarios. For example, an
adult who gets abdominal pain and minor urticaria after a full serv-
ing of well-cooked shellfish may reasonably be considered at lower
risk of a subsequent episode of anaphylaxis after eating a food la-
belled ‘‘may contain prawn’’ than a peanut-allergic child with re-
ported wheeze and collapse after consuming a tiny piece of
peanut butter on bread who just ate a wrapped cereal bar labelled
‘‘may contain peanut and other nuts’’. Evolving clinical practice
now also recognises that some allergen scenarios, such as baked
egg and milk in cakes and biscuits, are tolerated and could be ex-
pected to be safe for many individuals with egg or milk allergy. In
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these cases, expert clinical advice now permits dietary introduction
of milk and egg in these baked forms for appropriate individuals,
while still recommending continued avoidance of all unprocessed
forms of egg or milk. In practice, a dietary strategy similar to this
baked food strategy could also be recommended for other aller-
gen-containing ingredients or products should these be found to
have insignificant or inconsequential levels of allergens.
Clinical advice about labelling can also be inconsistent at times.
Anecdotally, some health professionals do deviate from the recom-
mended practice and openly advocate that patients ignore all or
certain precautionary labels. Consideration of analytical surveys
showing high allergen levels in some labelled products suggests
this to be a very risky strategy. At the same time, survey findings
that many labelled products have no or very little allergen illus-
trate the urgent need to make precautionary labelling of prepared
foods more meaningful.
A framework for the systematic and consistent application of
precautionary labelling based on clear and transparent criteria
clearly offers considerable scope for improving the advice provided
through clinicians to allergic patients. It will enable health profes-
sionals to communicate very clearly the (low) risk implied by the ab-
sence of a precautionary label. Also, through understanding the basis
of the risk assessment, they will be able to tailor their advice in a
more discriminating and individualised manner to their individual
patients, based on their knowledge of their allergological condition.
5.3. Food industry
As already discussed, the presence of unintended allergenic res-
idues in food results from the nature of allergens as contaminants
as well as from the current realities of the supply chain. Ever since
allergens became a public health issue, the question ‘‘how much is
too much’’ has been posed by food manufacturers and suppliers.
Unfortunately, this question has remained largely unanswered un-
til recently. In the meantime, manufacturers sought ways to warn
allergic consumers about the potential risk from the presence of
unintended allergens by the use of precautionary statements on
the label, such as ‘‘may contain’’. While initially welcomed by aller-
gic consumers, the spread of such statements soon reduced their
credibility. Another factor which detracted from their value was
the fact that different manufacturers applied different criteria to
decide when to use such a label and used different phrases to con-
vey this risk. This was perhaps not surprising since the same lack of
data which drove the use of such labels also prevented the devel-
opment of an agreed and consensual approach to assessing the risk
from unintended allergens. Also, as mentioned, some messages
from consumers indicate a desire for more differentiated informa-
tion to aid them in judging risk.
While manufacturers strive to minimise cross contamination
during manufacturing processes, the presence of unintended aller-
genic constituents by cross-contact will remain a reality for the
foreseeable future because of the economic necessity to utilize
shared processing facilities and lines. Consequently, precautionary
labelling will remain an important risk management and risk com-
munication tool. In this regard, the framework proposed in this re-
port has a number of important and positive implications for all
involved in the food supply chain.
Firstly, evidence-based reference doses defining a specific level
of protection and providing an agreed consensual basis for the
application of precautionary labelling will restore its credibility
and therefore its value as a risk management and communication
tool. In doing so, it will improve food safety for allergic consumers
by restoring trust and communicating a clear message.
Secondly, manufacturers will benefit from a common approach
to risk assessment, which can be applied right along the supply
chain. This will promote greater understanding of allergen
requirements between companies at different points in the supply
chain including the need for quantitative information on unintended
allergen content. In doing so, it will reduce the potential for
misunderstandings which can lead to product recalls. A further
advantage likely to flow from a set of agreed common standards
is an improvement in operational capacity, leading to economies.
As alluded to earlier, however, the proposed framework also
presents challenges. Achieving the standards required to avoid pre-
cautionary labelling may be quite difficult in some operations and
circumstances, particularly where allergen management has had to
be implemented in old facilities. As a result, some sectors will find
it difficult to maintain their current level of precautionary labelling
without significant investment.
Thirdly, allergen detection methods used for assessing the pres-
ence of allergen traces may find themselves at the limit of their
sensitivity for some of the action levels associated with large por-
tion sizes. There will therefore be an urgent need to be validate
their limits of detection in targeted food matrixes. Accurate aller-
gen detection methods will also be dependent on the effort of
developing recognised allergen reference materials. Analytical
information will then contribute to improve the accuracy of mon-
itoring and surveillance of allergens by the food industry.
Once widely accepted, a framework of consistent standards,
used by all industry and considered by regulatory authorities to
be highly protective, will also remove the fear of competitive dis-
advantage that might otherwise hold back implementation.
From an industry point of view, thought must also be given to
communicating to allergic consumers that a product has been
the subject of a risk assessment and is below the action level, until
such time as adoption is widespread. A reference of the type ‘‘this
product has been assessed through xxx’’ – could make a specific
reference to the proposed framework. The proposed approach will
have maximum impact and therefore accrue the expected benefits
to consumer safety and public health only if it is adopted widely.
Clearly this will require significant education and training, with a
particular focus on the very numerous medium and small compa-
nies who may find it difficult to access the relevant technical
expertise. The example of the implementation of VITAL in Australia
will provide useful experience in this regard.
5.4. Public health authorities
The development and implementation of a framework for aller-
gen risk assessment anchored in evidence-based reference doses
will give public health authorities, including regulators and enforce-
ment bodies, a more secure basis for enforcement activities when
allergen cross contamination is detected in a product, thereby pro-
viding greater clarity and more consistency for businesses in the
handling of food allergen incidents. In this regard, it may provide a
basis for assessing overall population health hazard associated with
certain allergen exposures in contaminated or recalled products and
be used to improve guidance about these hazards to industry as well
as allergic consumers and healthcare practitioners. This risk assess-
ment framework may also be a tool to provide scientific evidence to
support exemption claims from source labelling for ingredients
demonstrated to contain allergen content and expected product
exposures well below those described by reference dose limits.
6. Accepted level of risk
Widespread use of precautionary labelling could be viewed as an
attempt to prevent any and all types of reaction in every allergic
individual, i.e. trying to achieve zero risk, which is not a realistic pos-
sibility. The severity of adverse events varies significantly between
persons with a food allergy and depends on the nature and
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properties of the allergen, the amount of the allergen consumed and
the physiological state and genetic background of the patient. A pre-
requisite for public health authorities is therefore to share a broadly
similar outlook on the frequency of food allergic reactions that could
be accepted, differentiating between reactions of different degrees
of severity and aligned with the actual needs and behaviour of aller-
gic consumers. With regard to products with precautionary label
statements, some degree of reaction risk from consumption of these
products may be more acceptable from a public health standpoint if
it can be demonstrated that current or potential risks (e.g. negative
quality of life, adverse reactions from risk-taking behaviours, etc.)
could be lessened. Thus, the protection of allergic consumers is a
shared responsibility and regulators across the EU and beyond
should make that decision in consultation with all interested parties,
including allergic consumers, patient organisations, food busi-
nesses, scientists and healthcare professionals (i.e. medical doctors,
health centre physicians and dieticians) and public authorities.
Agreement between stakeholders on what can be achieved and the
resulting risk management objectives would form a sound basis
for progress, building on existing evidence about risk perception
and behaviours (Madsen et al., 2012; Health Council of the Nether-
lands, 2007). Once a political decision has been made on the tolera-
ble frequency of different types of adverse allergic effects, as
discussed above, allergen reference doses can be determined which
meet the appropriate level of protection and can be used by busi-
nesses and regulators to assess the levels of allergen cross contami-
nation that have been detected in a particular product. If a business
is able to ensure that this Reference Dose would not be exceeded by
estimated per meal consumption of the allergen-containing food
product in question, the precautionary labelling should be omitted
on that particular product (Health Council of the Netherlands,
2007). Implementation of such an approach is supported by the
observation that, as discussed in more detail in an accompanying pa-
per (ref), any given benchmark, such as a Reference Dose, actually
protects to a greater degree than the nominal level of protection, be-
cause of the way the benchmark is interpreted and implemented to
assure compliance. Thus, if a business is controlling allergen cross
contamination to a certain level, almost all products will contain
allergen below that level, if any at all. Products that contain allergen
at the action level would be in the minority.
7. How would risk managers apply these values in different
scenarios?
The effectiveness with which new standards can be applied,
monitored by businesses and enforced by authorities will be criti-
cal to their adoption and use. As already discussed, precautionary
allergen labelling has lost credibility and effectiveness (Barnett
et al., 2011b). The standards aim not only to harmonise the imple-
mentation of precautionary labelling across industry, but to limit
(or at least not increase) its extent. It will therefore be very impor-
tant to strike the correct balance between ensuring a sufficient
range of food choices to limit risk-taking by allergic consumers
and yet minimising reactions due to unintended allergen presence
below the reference dose. Setting reference doses also needs to
consider the adequacy of analytical techniques to detect the aller-
gens reliably at the concentrations that would be found in products
if unintended allergen was present around the action level.
Finally, it is paramount that any set of allergen reference doses
that are established are understood by consumers and the health
care community and can be used by them without reservations
to make informed choices. The basis for the reference doses se-
lected and the data underpinning those values need to be clear,
as do any assumptions that are made. The risk/benefit balance is
between protecting the allergic consumer as much as is practica-
ble, whilst enabling businesses to produce products that are
economically viable and that do not result in unnecessary restric-
tions in consumer choice and quality of life. This needs to be ex-
plained to the consumer and to health professionals, and the
improvements in comparison with the current situation set out.
8. Future perspectives
8.1. Global
Food allergy is of global and growing importance to public
health, affecting consumers’ quality of life (mainly children) and
making increasing demands on health service resources. Develop-
ing knowledge about the relationship between allergen dose and
population reactivity, as well as the tools to translate this knowl-
edge to practical action to improve safety and quality of life of
allergic consumers bring the possibility to manage food allergens
as effectively as other food safety hazards.
Optimal protection of allergic consumers against allergen risks
rests on the application of risk management practices based on sci-
entifically robust principles, shared across all stakeholders. This is
equally valid when prioritising food allergens on the basis of their
public health impact, as in the lists of regulated allergens.
Allergen labelling represents a critical tool for management and
needs to communicate the allergen status of products unambigu-
ously using simple, harmonized terms in local language to maximise
consumer understanding available upon demand. Precautionary
warnings must be applied consistently for unintended allergen pres-
ence using quantitative action levels and using harmonised phrases
to indicate such risks to assure integrity and retain relevance.
The global nature of today’s food supply chain dictates that
effective management depends on application of good practice
across all jurisdictions worldwide by all stakeholders i.e. regulators,
food manufacturers, retailers and caterers alike. Enshrining these
principles in a CODEX code of practice for the risk management
of food allergens that would reach out globally and describe a
consistent standard approach could be a possible way to achieve
this goal.
8.2. Promoting positive distinction
There is concern that allergen precautionary warnings are cur-
rently so devalued that they are ignored by a significant proportion
of food-allergic consumers and some health professionals do not con-
tradict their patients when they ignore such warnings. A current bar-
rier to effectively protecting allergic consumers is their inevitable
lack of understanding of the meaning of precautionary labelling in
the context of the disparate standards. However moving to the har-
monised system discussed in this series of papers will require clear
communication of the changes to those consumers, as well as to
health professionals. In particular, while the use of precautionary
warning labels remains voluntary, allergic consumers may want to
know whether a product that bears no warning does so because a risk
assessment referenced to accepted standards was conducted and
found no need for this label warning. Two different messages con-
cerning the interpretation of labelling could be construed; these are:
– A risk assessment has been conducted using a specified sys-
tem based on agreed allergen reference doses, as a result of
which a precautionary warning is warranted. The precau-
tionary statement would also need to be limited to one or
two phrases, whose use would be restricted to companies
using the system.
– A risk assessment has been conducted and a decision taken
that the risk is negligible, together with a positive message
to indicate this. Such a positive message could provide a
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useful incentive for companies to adopt the new framework,
effectively providing a ‘‘dividend’’ for the investment in
learning about it and implementing it.
Consumers with food allergies could then actively seek out the
2nd category of products, while understanding that the absence of
a warning does not guarantee that there is zero cross contamina-
tion risk. They should therefore have been advised by their health-
care practitioners that their allergy was such that the risk to them
was indeed negligible. There could also be a third category of prod-
ucts without any messages beyond mandatory labelling of regu-
lated allergens in which it is implied that the business has not
conducted a risk assessment of the appropriate rigour.
8.3. Need for frequent revisions
Allergen reference values developed as part of the work of this
group are based on varying levels of data. Whilst the numbers of
challenges in subjects with allergies to peanut, egg, milk and hazel-
nut appear to be sufficient to produce robust outcomes, this is not
so for some of the other major food allergens covered by the regu-
latory allergen labelling list in Europe and for some the data are
currently very sparse. Moreover, quality assessments of the avail-
able challenge data and models used in the determination of the
reference doses need to be conducted. As challenge data continue
to be produced for those food allergens for which some data exist
but are not yet fully sufficient to derive robust outcomes, the pro-
visional reference values currently put forward will need to be re-
viewed at suitable intervals, until the outcomes are considered to
be robust. Where the data currently available are not sufficient
to derive even provisional reference values, consideration should
be given to the possibility of using a ‘default’ reference value by
extrapolating from those food allergens where robust reference
values have been derived.
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Annex
Glossary for Expert Group
Term Definition
Hazard Inherent property of a substance or
situation having the potential to cause
an adverse effect to an organism,
system or (sub)population is exposed to
it
Exposure Concentration or amount of a particular
agent that reaches a target organism,
system, or (sub)population in a specific
frequency for a defined duration
Routes of exposure Different modes of entry into the
organism after contact, for example
dermal, ingestion, inhalation
Intake Amount of exposure to a substance as
part of food and/or water consumed
Risk Probability of an adverse effect in an
organism, system or (sub)population
caused under specified circumstances of
exposure to a substance or situation
Safety Practical certainty that adverse effect
swill not arise upon exposure to a
substance under defined exposure
circumstances
Risk factors Any characteristic of the patient,
environment or food which can alter
the likelihood or severity of an adverse
reaction
Host factors Factors pertaining specifically to the
host or patient, such as genetics,
medical conditions, etc.
Event factors Factors relating to the event or exposure
occasion, such as place, circumstances
etc
Assessment factor Numerical adjustment used to
extrapolate from experimentally
determined (dose–response)
relationships to estimate the agent
exposure below which an adverse effect
is not likely to occur
Uncertainty factor Reductive factor by which an observed
or estimated no-observed-adverse
effect level (NOAEL) is divided to arrive
at a criterion or standard that is
considered safe or without appreciable
risk
Related terms: Assessment factor, Safety
factor
Safety factor Composite (reductive) factor by which
an observed or estimated no-observed
(continued on next page)
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adverse-effect level (NOAEL) is divided
to arrive at a criterion or standard that
is considered safe or without
appreciable risk
Related terms: Assessment factor,
Uncertainty factor
LOAEL Lowest Observed Adverse Effect Level –
in a controlled experimental study the
lowest dose which results in an adverse
effect
LOEL Lowest Observed Effect Level – in a
controlled experimental study the
lowest dose which results in any
observable effect
NOAEL No Observed Adverse Effect Level – in a
controlled experimental study the
highest dose which does not result in an
adverse effect
NOEL No Observed Effect Level – in a
controlled experimental study the
highest dose which does not result in
any observable effect
Benchmark dose A dose of an allergenic food that when
consumed produces a reaction in a
predetermined proportion of the
susceptible (allergic) population
Eliciting dose The dose in a dose distribution which is
predicted to provoke reactions in a
defined proportion of allergic




The minimum dose that elicits an effect
in an individual in a challenge study –





Dose distribution The plot describing the cumulative
proportion of (allergic) individuals
reacting as a function of dose, based on
their MEDs
Dose Total amount of an agent administered
to, taken up by, or absorbed by an
organism, system, or (sub)population
Reference dose An estimate of the daily exposure dose
that is likely to be without deleterious
effect even if continued exposure occurs
over a lifetime. In the case of allergens,
since acute exposure defines risk for
adverse deleterious effect, the exposure
estimate is derived from amount per
eating occasion
Related term: Acceptable daily intake
Guidance value Value, such as concentration in air or
water, that is derived after allocation of
the reference dose among the different
possible media (routes) of exposure
The aim of the guidance value is to
provide quantitative information from
risk assessment to the risk managers to
enable them to make decisions
(See also Reference dose)
Threshold Dose or exposure concentration of an
agent below which a stated effect is not
observed or expected to occur
It lies in an interval bounded by the
LOAEL (upper) and NOAEL (lower)
Action level The concentration of an allergen in a
product below which a precautionary
label is deemed unnecessary (derived
from reference value)
Precautionary label An advisory statement or warning for
consumers accompanying, or available
at point of sale of, foodstuffs which
provides risk communication to sub-
populations with special dietary
requirements, e.g. phenylalanine
intolerance, lactose intolerance, milk
allergy
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